P021

What it is

P21, more commonly written as P021 in the peer-reviewed literature, is an experimental neurotrophic peptide mimetic developed in the context of ciliary neurotrophic factor research. CNTF is a cytokine-like neurotrophic factor with biological effects on neuronal survival, differentiation, and glial biology, but the full protein is not readily translated into routine brain-directed drug therapy because of size, delivery, tolerability, and blood-brain-barrier limitations^{[12 ]}. P021 was designed as a smaller, chemically modified compound intended to preserve selected neurotrophic properties while improving drug-like handling in preclinical models^{[4 ,7 ,12 ]}.

The first widely cited experimental report, published by Li and colleagues in FEBS Letters in 2010, described P21 as Ac-DGGLAG-NH2 and reported that peripheral administration improved learning and memory measures in normal adult C57BL/6 mice while promoting hippocampal neurogenesis and synaptic plasticity^{[4 ]}. Later papers generally use the name P021 and describe the compound as a CNTF-derived peptidergic agent that was modified with adamantylated glycine to increase stability, lipophilicity, and brain penetration^{[5 ,7 ,12 ]}.

Mechanistically, P021 is discussed in relation to neurogenesis, synaptic plasticity, brain-derived neurotrophic factor, leukemia inhibitory factor signaling, CREB activation, GSK3 beta regulation, tau phosphorylation, and amyloid-beta pathology in animal models^{[4 –12 ]}. These pathways are plausible targets in neurodegeneration research, but they are not clinical indications. No human trial establishing safety, dosing, or efficacy was identified for this draft.

Administration in the animal literature has included peripheral injection and oral delivery through formulated diet, depending on the experiment^{[4 –11 ]}. Those descriptions are study methods, not human-use instructions. P021 products advertised online for cognition, neurogenesis, or Alzheimer disease prevention should not be treated as equivalent to pharmaceutical development material used in controlled preclinical research.

The shorthand “P21” creates a search problem because p21 also refers to CDKN1A, a cyclin-dependent kinase inhibitor and tumor-suppressor pathway protein. This page covers the neurotrophic peptide mimetic P021/P21 only, not CDKN1A biology or oncology literature.

Regulatory status

P021 is not FDA-approved for Alzheimer disease, cognitive impairment, Down syndrome, CDKL5 deficiency disorder, retinal disease, traumatic brain injury, neurogenesis enhancement, longevity, or any other indication in the United States. No FDA-approved prescribing information, approved product label, or FDA-reviewed clinical-use framework was identified for P021 in the sources reviewed for this draft^{[1 –3 ]}.

503A and 503B compounding

P021 was not identified on FDA’s April 22, 2026 503A category list of nominated bulk drug substances^{[2 ]}. Absence from that category list should not be interpreted as approval or prohibition by itself; it means the draft did not identify a current FDA 503A nomination category for P021. Under FDA’s 503A framework, a state-licensed pharmacy or physician compounding from a bulk drug substance must meet statutory conditions, including use of substances that comply with an applicable USP/NF monograph, are components of FDA-approved drugs when no monograph exists, or appear on FDA’s 503A bulks list^{[1 ]}.

For outsourcing facilities under 503B, FDA states that bulk drug substances generally may be used only when the compounded drug appears on FDA’s shortage list at the relevant time or the substance appears on FDA’s 503B bulks list because FDA has found a clinical need^{[1 ]}. This review did not identify P021 on a current 503B pathway^{[1 ]}.

Controlled-substance status

P021 was not identified in federal controlled-substance schedules in 21 CFR Part 1308 as reviewed on May 7, 2026^{[3 ]}. Controlled-substance status is separate from FDA approval, compounding eligibility, lawful marketing, and product quality. A compound can be unscheduled and still be an unapproved drug if marketed for human treatment claims.

No notable international therapeutic approval was identified for P021. The visible literature remains preclinical and academic, with development-related disclosures and patents noted in some papers^{[7 –8 ,12 ]}. Date of last regulatory verification: May 7, 2026.

Research summary

P021’s evidence base is preclinical. The 2010 Li paper reported that adamantane-containing neurotrophic peptides improved learning and memory measures, promoted neurogenesis, and increased synaptic plasticity markers in mice^{[4 ]}. The article is important because it provides the design rationale and early behavioral biology for P21/P021. It does not establish human efficacy, clinical safety, or disease treatment.

Alzheimer disease mouse models — Kazim 2014, Baazaoui 2017

Alzheimer disease mouse models account for much of the subsequent research. Kazim and colleagues studied chronic oral treatment with P021 in the triple-transgenic 3xTg-AD mouse model, beginning at moderate and severe pathology stages^{[5 ]}. The study reported effects on tau pathology, amyloid-beta pathology, neurogenesis, neuronal plasticity, and cognition, with proposed involvement of BDNF/TrkB/PI3K/Akt/GSK3 beta signaling^{[5 ]}. This is one of the more detailed disease-model papers, but it remains an animal study in a model that only partially represents human Alzheimer disease.

Baazaoui and Iqbal later examined earlier treatment timing in 3xTg-AD mice. In a 2017 Journal of Alzheimer’s Disease paper, they reported that P021 treatment initiated before overt pathology reduced neurodegeneration, amyloid-beta and tau pathology measures, episodic memory impairment, and mortality in female 3xTg-AD mice^{[6 ]}. A related 2017 Alzheimer’s Research & Therapy paper focused on dendritic and synaptic deficits and reported that long-term P021 treatment beginning at about 3 months of age rescued selected dendritic and synaptic markers, boosted neurogenesis, and improved cognitive measures in the same general mouse-model context^{[7 ]}.

Prenatal/postnatal extensions — Wei 2020/2021

Early-development studies extended the concept into prenatal and postnatal windows. Wei and colleagues reported that prenatal to early postnatal P021 treatment in 3xTg-AD mice affected Alzheimer-like behavior and pathology later in life^{[8 ]}. A separate 2021 paper reported that treatment beginning during early postnatal development prevented Alzheimer-like behavior and synaptic dysfunction in young 3xTg-AD mice^{[9 ]}. These studies are mechanistically interesting but are not directly translatable into human prenatal, pediatric, or preventive use.

Down syndrome — Kazim 2017

Down syndrome research has also used P021 in the Ts65Dn mouse model. Kazim and colleagues reported that early neurotrophic pharmacotherapy with P021 rescued developmental delay and Alzheimer-like memory deficits in the Ts65Dn model^{[10 ]}. This is relevant because Down syndrome is associated with altered brain development and increased Alzheimer disease risk, but a mouse-model response does not establish a therapy for people with Down syndrome.

Retinal aging and CDKL5 — Liu 2019, Mottolese 2024

Other preclinical work explored retinal and neurodevelopmental contexts. Liu and colleagues reported inhibition of AMD-like pathology in aged rats and 3xTg-AD mice with P021 treatment^{[11 ]}. Mottolese and colleagues evaluated a CNTF small-molecule peptide mimetic in CDKL5 deficiency models and found positive effects in vitro, but chronic in vivo P021 treatment in Cdkl5 knockout mice produced limited behavioral benefit and did not reproduce the expected BDNF increase^{[13 ]}. This negative or mixed in vivo result is important because it shows that P021 effects may depend heavily on disease model, timing, delivery, and biological context.

Quality-of-evidence assessment

No randomized human clinical trials of P021 were identified. No peer-reviewed evidence was found establishing P021 as a treatment for Alzheimer disease, dementia, Down syndrome, CDKL5 deficiency disorder, age-related macular degeneration, traumatic brain injury, “brain repair,” or cognitive enhancement in humans. The current evidence quality is animal-model and in vitro research only, with repeated publications from overlapping research groups. The strongest defensible statement is that P021 has been studied as a CNTF-derived neurotrophic peptide mimetic in several preclinical neurologic and retinal models.

Public discourse

No qualifying named public-podcast, physician-influencer, or public-figure sources with verifiable primary quotes were identified for P021 during this review. Public-facing claims found in peptide-vendor and nootropic commentary generally extrapolated from the preclinical P021 literature and were not used as factual support.

Academic discussion of P021 is covered in the Research Summary because it is peer-reviewed scientific discourse rather than public commentary. Vendor pages and anonymous forum posts were excluded because they either lacked independent sourcing, made human-use claims beyond the evidence, or provided sourcing guidance that is outside this site’s editorial standards.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

P021 has no FDA-approved prescribing information. There is no FDA-reviewed adverse-reaction table, contraindication list, drug-interaction section, pregnancy/lactation language, pharmacovigilance dataset, carcinogenicity assessment, or route-specific human safety framework^{[1 –3 ]}.

Animal-model tolerability

Animal studies frequently describe P021 as well tolerated in the specific models tested, and the 2016 review characterized P021 as lacking adverse effects associated with native CNTF or BDNF molecules^{[12 ]}. That statement should be interpreted narrowly. Absence of obvious toxicity in mouse or rat studies does not establish safety in humans, especially for chronic use, neurodevelopmental exposure, pregnancy, pediatric populations, neurodegenerative disease, or intranasal/injectable grey-market formulations.

Theoretical concerns

Theoretical concerns include immune responses to modified peptides, off-target neurotrophic signaling, developmental effects, effects on seizure threshold or neuropsychiatric symptoms, interactions with neurologic medications, and risks from products of uncertain identity. The adamantane-containing modification is central to the compound’s design rationale, but it also means P021 is not simply a natural CNTF fragment.

Translation gaps

Mottolese and colleagues’ CDKL5 study is a useful cautionary example because in vitro findings did not translate cleanly into broad in vivo benefit in the mouse model^{[13 ]}. Mechanistic plausibility and biomarker effects are not substitutes for clinical safety and outcome data.

Grey-market product risks

Grey-market P021 introduces additional safety risks unrelated to the academic molecule itself: inaccurate sequence, incorrect salt form, poor purity, peptide degradation, endotoxin contamination, microbial contamination, solvent residues, nonsterile preparation, and concentration errors. These risks are especially relevant when products are marketed for intranasal or injectable use.

Long-term human safety data are not available. P021 should be described as a preclinical research compound, not as a human neuroregenerative therapy.

Available through

P021 is not currently available through FDA-compliant channels in the United States as of 2026-05-07^{[1 –3 ]}. ProPeptideGuide does not link to or endorse grey-market vendors.